• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾移植后多次再入院的发生率及危险因素

Incidence of and Risk Factors for Multiple Readmissions after Kidney Transplantation.

作者信息

Schucht Jessica, Davis Eric G, Jones Christopher M, Cannon Robert M

出版信息

Am Surg. 2020 Feb 1;86(2):116-120.

PMID:32167042
Abstract

Unplanned readmission is often used as a surgical quality metric. A subset of kidney transplant recipients undergos multiple readmissions (MRs), although the incidence and risk factors are not well described. The aim of this study was to evaluate risk factors for MR after deceased donor kidney transplantation. All patients undergoing deceased donor kidney transplantation at a single center over a three-year period were analyzed retrospective chart review for factors associated with MR. values <0.05 were considered significant. Of 141 patients, the 30-day readmission rate was 26.2 per cent. MR occurred in 43 (30.5%) patients. Age, race, gender, initial organ function, and dialysis vintage were not associated with MR. Diabetic recipients, those who received basiliximab induction, those with acute rejection, and those with unplanned reoperations were at increased risk for MR. Infection was the most common reason for initial readmission in patients with MR (23.3%). One-year patient survival and death-censored graft survival were reduced for patients with MR. MRs are required for 30 per cent of kidney transplant recipients, primarily because of infection and immunologic causes. Recipients with diabetes and those who have acute rejection are at greatest risk.

摘要

非计划再入院常被用作手术质量指标。一部分肾移植受者会经历多次再入院(MRs),尽管其发生率和危险因素尚未得到充分描述。本研究的目的是评估尸体供肾移植后MR的危险因素。对一个中心三年内接受尸体供肾移植的所有患者进行回顾性病历审查,分析与MR相关的因素。P值<0.05被认为具有统计学意义。在141例患者中,30天再入院率为26.2%。43例(30.5%)患者发生了MR。年龄、种族、性别、初始器官功能和透析时间与MR无关。糖尿病受者、接受巴利昔单抗诱导治疗的患者、发生急性排斥反应的患者以及接受非计划再次手术的患者发生MR的风险增加。感染是MR患者首次再入院最常见的原因(23.3%)。MR患者的1年患者生存率和死亡审查后的移植物生存率降低。30%的肾移植受者需要MR,主要原因是感染和免疫因素。糖尿病受者和发生急性排斥反应的患者风险最高。

相似文献

1
Incidence of and Risk Factors for Multiple Readmissions after Kidney Transplantation.肾移植后多次再入院的发生率及危险因素
Am Surg. 2020 Feb 1;86(2):116-120.
2
A single-center experience with six-antigen-matched kidney transplants.六抗原匹配肾移植的单中心经验
Arch Surg. 1995 Mar;130(3):277-82. doi: 10.1001/archsurg.1995.01430030047008.
3
Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.低风险肾移植受者中胸腺球蛋白与巴利昔单抗诱导治疗的单中心经验
Transplant Proc. 2018 Jun;50(5):1285-1288. doi: 10.1016/j.transproceed.2018.02.088.
4
Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.巴利昔单抗在小儿肾移植中诱导治疗的疗效优于抗淋巴细胞球蛋白
Nephrol Dial Transplant. 2002 Jul;17(7):1304-9. doi: 10.1093/ndt/17.7.1304.
5
An analysis of unplanned return to the operating room following deceased donor kidney transplantation.供体肾移植术后非计划性重返手术室的分析。
Am J Surg. 2019 Jul;218(1):27-31. doi: 10.1016/j.amjsurg.2019.01.018. Epub 2019 Jan 24.
6
Does Distance to Transplant Center Affect Post Kidney Transplant Readmission Rates?与移植中心的距离会影响肾移植后的再入院率吗?
Am Surg. 2019 Aug 1;85(8):834-839.
7
Diabetes mellitus after kidney transplantation in Japanese patients: The Japan Academic Consortium of Kidney Transplantation study.日本患者肾移植后的糖尿病:日本肾移植学术联盟研究
Int J Urol. 2017 Mar;24(3):197-204. doi: 10.1111/iju.13253. Epub 2016 Nov 11.
8
Hospital readmissions in diabetic kidney transplant recipients with peripheral vascular disease.患有外周血管疾病的糖尿病肾病移植受者的医院再入院率。
Clin Transplant. 2018 Jun;32(6):e13271. doi: 10.1111/ctr.13271. Epub 2018 May 22.
9
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.巴利昔单抗与安慰剂用于控制肾移植受者急性细胞排斥反应的随机试验。CHIB 201国际研究组。
Lancet. 1997 Oct 25;350(9086):1193-8. doi: 10.1016/s0140-6736(97)09278-7.
10
Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.胸腺球蛋白和巴利昔单抗在急性排斥反应和移植肾功能延迟高风险肾移植患者中的疗效与安全性。
Exp Clin Transplant. 2013 Aug;11(4):310-4. doi: 10.6002/ect.2012.0103. Epub 2012 Nov 1.

引用本文的文献

1
Incidence, predictors, and outcomes of early hospital readmissions after kidney transplantation: Systemic review and meta-analysis.肾移植后早期医院再入院的发生率、预测因素及结局:系统评价与荟萃分析
Front Med (Lausanne). 2022 Nov 4;9:1038315. doi: 10.3389/fmed.2022.1038315. eCollection 2022.